Domo’s board also includes its chief executive, Lorand Szarvadi, and Lucian Ghitescu.
Dinu was recruited only several months after Lucian Ghitescu joined the company coming from Samsung where he worked as the head of the home appliance division. Lorand Szarvadi remained Domo’s CEO.
“Dragos Dinu has been a member of the board of directors of Domo since October 1. The board members are Dragos Dinu, Lucian Ghitescu and Lorand Szarvadi. I am still the company’s chief executive officer,” Lorand Szarvadi, Domo’s CEO said.
“Domo also has a executive committee, which comprises the board members and CFO Alexandru Mnohoghitnei and CCO (chief commercial officer e.n.) Zsuzsanna Teglas Szarvadi.”
After almost four years of providing health care industry advice, Dragos Dinu, 45, decided to return to the business world in a company that posted EUR165 million sales last year.
When he decided to leave A&D Pharma, Dinu was running a company listed on the London Stock Exchange, which generated EUR500 million revenue and became market leader during his reign.
By joining Domo, Dragos Dinu started working in IT and electronics retail, a free and fiercely competitive market, unlike the pharmaceuticals market, which is largely regulated by the government.
Dragos Dinu worked for A&D Pharma for 13 years, where he started as a sales manager with the Plurifarm unit. Even though people associate his name with the pharmaceutical industry, Dinu admitted that when he first started working he unloaded gas cylinder trucks, played professional soccer, had journalist and engineer jobs, wrote poetry, waited tables and served drinks as a bartender.
His decision to leave A&D Pharma in 2008 took many people by surprise. He said at the time “new times, new goals are coming and I think it was high time for a change for both me and the company.”
He has recently told BUSINESS Magazin he felt that most pharmaceutical retail and distribution clients kept seeing him as a competitor even after he left A&D Pharma, which is why they did not seek his advice, leaving him with only drug producers as business partners.
(English version by Loredana Fratila-Cristescu)